Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655487 | 0.91 | SLC18A3 (0.47) | SLC18A3SIGMAR1CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1366490 | 0.91 | SLC18A3 (0.47) | SLC18A3SIGMAR1CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL242194 | 0.86 | SLC18A3 (0.45) | SLC18A3SIGMAR1GRIN2BDRD2GAA | |
| SCHEMBL1366116 | 0.86 | SLC18A3 (0.45) | SLC18A3SIGMAR1GRIN2BDRD2GAA | |
| SCHEMBL1367144 | 0.86 | SLC18A3 (0.45) | SLC18A3SIGMAR1GRIN2BDRD2GAA | |
| SCHEMBL1364725 | 0.82 | NOTUM (0.42) | SLC18A3SIGMAR1DRD2DHFR | |
| SCHEMBL41763 | 0.81 | — | — | |
| SCHEMBL190417 | 0.81 | SLC18A3 (0.67) | SLC18A3SIGMAR1GRIN2BDRD2GAA | |
| SCHEMBL4176060 | 0.80 | SLC18A3 (0.69) | SLC18A3SIGMAR1GRIN2BCYP2D6CYP2C19 | |
| Benzene SCHEMBL23070411 | 0.78 | SLC18A3 (0.64) | SLC18A3SIGMAR1GRIN2BDRD2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1028 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | claimed |
| US-20240190885-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-06-13 | — | — | US | claimed |
| CN-117946031-A | Substituted aromatic phenol derivatives of KNa1.1 channel inhibitors | 北京大学 | 2024-04-30 | — | — | CN | claimed |
| WO-2023001268-A1 | CHRYSIN DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳枫语生物医药科技有限公司 | 2023-01-26 | — | — | WO | claimed |
| CN-113773293-A | Chrysin derivative and preparation method thereof | 深圳枫语生物医药科技有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-113768915-A | Application of chrysin derivative in preparation of medicine | 深圳枫语生物医药科技有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-108586335-B | 2-hydroxybenzamide-1, 2,3, 4-tetrahydroisoquinoline-O-carbamate compound and preparation method thereof | 南阳师范学院 | 2020-07-03 | — | — | CN | claimed |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-07-31 | — | — | US | claimed |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-22 | — | — | US | claimed |
| US-20160244408-A1 | CARBAZOLE DERIVATIVES ACTING ON 5-HT7 RECEPTOR | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-08-25 | — | — | US | claimed |
| EP-0023569-B1 | DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-06-22 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| EP-0039051-A2 | Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1981-11-04 | — | — | EP | claimed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | claimed |
| EP-0020303-A1 | Guanidines, process for their preparation, pharmaceutical preparations containing such compounds and their application | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | claimed |
| EP-0020304-A1 | Guanidines, process for their preparation, pharmaceutical preparations containing such compounds and their application | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | claimed |
| US-4139626-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1979-02-13 | — | — | US | claimed |
| US-4110536-A | ANTIARRHYTHMIA | MILES LABORATORIES, INC. (US) | 1978-08-29 | — | — | US | claimed |
| US-4006232-A | Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins | MILES LABORATORIES, INC. (US) | 1977-02-01 | — | — | US | claimed |
| US-3983107-A | ARTERIOSCLEROSIS | PFIZER INC. (US) | 1976-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190885-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, NRAS, APC | SLC18A3 4880/4885SIGMAR1 4375/4885GRIN2B 4617/4885 |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | SLC18A3 4665/4885SIGMAR1 1547/4885GRIN2B 4618/4885 |
| US-10035795-B1 | Phenothiazine derivatives having CaM inhibitory activity | CALM1, CAMK4, CAMK1 | SLC18A3 2455/4885SIGMAR1 2571/4885GRIN2B 3395/4885 |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | SLC18A3 1090/4885SIGMAR1 1625/4885GRIN2B 1364/4885 |
| US-20160244408-A1 | CARBAZOLE DERIVATIVES ACTING ON 5-HT7 RECEPTOR | HTR7, HTR3A, HTR3B | SLC18A3 578/4885SIGMAR1 200/4885GRIN2B 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.